Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review

Prognosis of early stage non-small cell lung cancer (eNSCLC) is poor even when treated radically with surgery and (neo)adjuvant chemotherapy (Cht). The discovery of tyrosine kinase inhibitors (TKIs) for oncogene addicted NSCLC and immune checkpoint inhibitors (ICIs) have revolutionised the therapeut...

Descripción completa

Detalles Bibliográficos
Autores principales: Ortega-Franco, Ana, Calvo, Virginia, Franco, Fabio, Provencio, Mariano, Califano, Raffaele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815374/
https://www.ncbi.nlm.nih.gov/pubmed/33489825
http://dx.doi.org/10.21037/tlcr-20-546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815374/
https://www.ncbi.nlm.nih.gov/pubmed/33489825
http://dx.doi.org/10.21037/tlcr-20-546

Ejemplares similares